What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?

References

• Wimo A, Guerchet M, Ali GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2016 Aug 29;13:1–7.
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Pemberton-Ross P, Gomez Montero M, et al. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2020 Sep;20:1–8.
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Hendrix S, Harrison JE. FDA position statement “Early Alzheimer’s disease: developing drugs for treatment, Guidance for Industry”. Alzheimers Dement (N Y). 2019;5:13–19.
   PubMedGoogle Scholar
• Cole MA, Seabrook GR. On the horizon-the value and promise of the global pipeline of Alzheimer’s disease therapeutics. Alzheimers Dement (N Y). 2020;6(1):e12009.
   PubMedGoogle Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6(1):e12050.
   PubMedGoogle Scholar
• Biogen. FDA accepts Biogen´s aducanumab biologics license application for Alxheimer´s disease with priority review Canbridge, Mass. US: Biogen; 2020 cited 2020 Sept 11, 2020 Sept 11. Available from https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application
   Google Scholar
• Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020 Aug 12;12(1):95.
   PubMed Web of Science ®Google Scholar
• Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr;15(5):455–532.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Editorial: A Is for Amyloid. J Prev Alzheimers Dis. 2020;7(3):140–141.
   PubMed Web of Science ®Google Scholar
• Plascencia-Villa G, Perry G. Status and future directions of clinical trials in Alzheimer’s disease. Int Rev Neurobiol. 2020;154:3–50.
   PubMed Web of Science ®Google Scholar
• Idrus AA. ‘Trick or treat?’ Analysts react to Biogen’s aducanumab surprise. Fierce Biotech. 2020. Available from: https://www.fiercebiotech.com/biotech/trick-or-treat-analysts-react-to-biogen-s-aducanumab-surprise
   Google Scholar
• Wey J. Biogen touts Alzheimer’s drug data, but ducks analysts’ key regulatory questions. S&P Global Market Intelligence; 2019. [2020 Sept 12]. Available from https://www.spglobal.com/marketintelligence/en/news-insights/trending/L3CC3OYYCIAXTu1lmRPmMg2
   Google Scholar
• Hlavka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. RAND; 2018.
   Google Scholar
• Liu JL, Hlavka JP, Hillestad R, et al. Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer’s Treatment. Santa Monica, Calif.: RAND Corporation; 2017.
   Google Scholar
• Andersson E, Janelidze S, Lampinen B, et al. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease. Neurobiol Aging. 2020 Jul;25(95):143–153.
   Google Scholar
• Mattsson-Carlgren N, Andersson E, Janelidze S, et al. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv. 2020 Apr;6(16):eaaz2387.
   PubMed Web of Science ®Google Scholar
• Wimo A, Ballard C, Brayne C, et al. Health economic evaluation of treatments for AD: impact of new diagnostic criteria. J Intern Med. 2014 Mar;275(3):304–316.
   PubMed Web of Science ®Google Scholar
• Skoldunger A, Johnell K, Winblad B, et al. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease–a simulation study. Curr Alzheimer Res. 2013 Feb;10(2):207–216.
   PubMed Web of Science ®Google Scholar
• Green C, Handels R, Gustavsson A, et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: an open-source modeling framework. Alzheimers Dement. 2019 Aug 8;15(10):1309–1321.
   Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997 May-Jun;6(3):217–227.
   PubMed Web of Science ®Google Scholar
• IPECAD. International pharmaco-economic collaboration on Alzheimer’s disease Stockholm. IPECAD; 2020. [cited 2020 Sept 12]. Available from https://ipecadgroup.wordpress.com/
   Google Scholar
• Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr Med Chem. 2008;15(24):2433–2455.
   PubMed Web of Science ®Google Scholar
• Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673–2734.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018 Nov;14(11):653–666.
   PubMed Web of Science ®Google Scholar
• Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Mar 11;385(9963):2256–2263.
   Google Scholar
• Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol. 2017 Jun;13(6):327–339.
   PubMed Web of Science ®Google Scholar
• Wimo A. The end of the beginning of the Alzheimer’s disease nightmare: a devil’s advocate’s view. J Alzheimers Dis. 2018;64(s1):S41–S46.
   PubMedGoogle Scholar
• Tomaszewski S, Gauthier S, Wimo A, et al. Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer’s disease: socio-economic considerations modeled on treatments for tuberculosis, HIH/AIDS and breast cancer. J Prev Alzheimers Dis. 2016;3(3):164–172.
   PubMedGoogle Scholar
• Comer B. Six drug pricing models have emerged to improve product access and affordability [Web page]. PWC; 2019. [cited 2020 Sept 12]. Available from: https://www.pwc.com/us/en/industries/health-industries/library/6-drug-pricing-models.html
   Google Scholar
• Vreman RA, Leufkens HGM, Kesselheim AS. Getting the right evidence after drug approval. Front Pharmacol. 2020;11:569535.
   PubMed Web of Science ®Google Scholar